Publication
Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Authors not recorded
J Oral Pathol Med2016PMID 25677871stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
- drugCetuximabcivic_curation1.00
- geneEGFcivic_curation1.00
- variantEGF EXPRESSIONcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25677871
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGF EXPRESSION1 | ||||||||
| Cetuximab | Head and Neck Squamous Cell Carcinoma | Predictive | D | Supports Resistance | 3 | accepted | EID8263 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amp… (full text at CIViC) PMID 25677871 · Ansell et al., 2016 · Open in CIViC | civic |